myelofibrosis
Haematology · 2013–2025
7decisions
3medicines
3carried consumer input
26individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| fedratinib Treatment of intermediate-2 and high-risk myelofibrosis (primary, post-polycythaemia vera, or post-essential thrombocythaemia) in patients who have had prior… | May 2025 | Not recommended | 8 individuals |
| fedratinib Treatment of patients with intermediate-2/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia… | Nov 2025 | Recommended | no section in document |
| momelotinib Treatment of intermediate or high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in… | Nov 2024 | Recommended with restriction | 16 individuals |
| ruxolitinib First-line or second-line management of myelofibrosis (primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia… | Jul 2016 | Recommended | none received |
| ruxolitinib First-line or second-line management of myelofibrosis in patients satisfying certain clinical criteria, including intermediate-2, high-risk, and intermediate-1… | Mar 2015 | Recommended | none received |
| ruxolitinib Second-line treatment of myelofibrosis in patients with intermediate-2 or high-risk disease (according to IPSS) who are resistant, refractory, intolerant, or… | Jul 2014 | Deferred | 2 individuals |
| ruxolitinib Treatment of disease-related symptoms in patients with intermediate or high-risk primary (idiopathic) myelofibrosis, post-polycythemia vera myelofibrosis or… | Jul 2013 | Not recommended | unclear |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.